GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyfuse Biomedical KK (TSE:4892) » Definitions » Accounts Receivable

Cyfuse Biomedical KK (TSE:4892) Accounts Receivable : 円17.12 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Cyfuse Biomedical KK Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Cyfuse Biomedical KK's accounts receivables for the quarter that ended in Dec. 2023 was 円17.12 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Cyfuse Biomedical KK's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 49.77.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Cyfuse Biomedical KK's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was 円367.14.


Cyfuse Biomedical KK Accounts Receivable Historical Data

The historical data trend for Cyfuse Biomedical KK's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyfuse Biomedical KK Accounts Receivable Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Accounts Receivable
19.99 57.69 13.58 17.12

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only 13.58 1.22 1.17 0.56 17.12

Cyfuse Biomedical KK Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Cyfuse Biomedical KK Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Cyfuse Biomedical KK's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=17.118/31.383*91
=49.77

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Cyfuse Biomedical KK's accounts receivable are only considered to be worth 75% of book value:

Cyfuse Biomedical KK's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(3873.773+0.75 * 17.118+0.5 * 46.045-1011.34
-0-0)/7.8943
=367.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Cyfuse Biomedical KK Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Cyfuse Biomedical KK's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyfuse Biomedical KK (TSE:4892) Business Description

Traded in Other Exchanges
N/A
Address
3-5-27, Mita, West Wing-1st Floor. Sumitomo Fudosan Mita Twin Building, Minato-ku, Tokyo, JPN
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine related products.

Cyfuse Biomedical KK (TSE:4892) Headlines

No Headlines